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Abstract. A series of 73 bisphosphonium salts and 10 monophosphonium salt 
derivatives were synthesized and tested in vitro against several wild type and resistant 
lines of Trypanosoma brucei (T. b. rhodesiense STIB900, T. b. brucei strain 427, 
TbAT1-KO, and TbB48). More than half of the compounds tested showed a 
submicromolar EC50 against these parasites. The compounds did not display any cross-
resistance to existing diamidine therapies, such as pentamidine. In most cases, the 
compounds displayed a good selectivity index versus human cell lines. None of the 
known T. b. brucei drug transporters were required for trypanocidal activity, although 
some of the bisphosphonium compounds inhibited the Low Affinity Pentamidine 
Transporter. It was found that phosphonium drugs act slowly to clear a trypanosome 
population, but that only a short exposure time is needed for irreversible damage to the 
cells. A Comparative Molecular Field Analysis Model (CoMFA) was generated to gain 
insights into the SAR of this class of compounds, identifying key features for 
trypanocidal activity.  
 
 
 
Keywords: phosphonium salt, chemotherapy, protozoa, Trypanosoma brucei, sleeping 
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Introduction 
Human African trypanosomiasis (HAT or sleeping sickness) is a parasitic disease 
caused by infection with two subspecies of trypanosomes: Trypanosoma brucei 
gambiense and T. b. rhodesiense. HAT is endemic in 36 countries of sub-Saharan 
Africa and, together with the corresponding condition in domestic animals, is a major 
cause of suffering and poverty for the affected population. If left untreated, the disease 
is usually fatal.1 However, the treatment options are scarce as few drugs are available 
(i.e., suramin, pentamidine, melarsoprol, eflornithine, and recently, the combination 
therapy nifurtimox-eflornithine). These are far from being ideal due to ineffectiveness 
to some trypanosome species or stages of the infection, as well as to toxicity, a 
parenteral mode of administration and the emergence of resistance.2, 3  
The antitrypanosomal activity of benzyltriphenylphosphonium salts against T. brucei 
was first reported in 1979 by Kinnamon et al..4 Some compounds were curative in a 
murine model of T. b. rhodesiense infection. However, the study of the potential of 
phosphonium salts as antiprotozoal agents was not followed up by any research group 
as shown by the lack of literature on this subject in the last 30 years. We recently 
regained interest in the antiparasitic activity of phosphonium salts with the discovery of 
a series of benzophenone-derived bisphosphonium salt derivatives that showed a 
marked antileishmanial activity in vitro.5 In Leishmania, the best compound of the 
series (i.e., 4,4’-bis((tri-n-pentylphosphonium)methyl)benzophenone dibromide) was 
found to target the mitochondria of the parasite, inhibiting complex II of the respiratory 
chain.5 Since some of these benzophenone compounds also showed interesting activity 
against T. b. rhodesiense,6 we decided to prepare new derivatives to systematically 
examine the structure-activity relationship of antitrypanosomal phosphonium 
compounds. Hence, we synthesized 60 new phosphonium salt derivatives with 
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variations in the following parts of the lead structure: (a) linker type, (b) linker length, 
(c) number of cations, (d) nature of the counterion, and (e) nature of the phosphonium 
groups substituents R1, R2, R3 (Chart 1). 
 
Chart 1. General Structure of Benzophenone-derived Bisphosphonium Salt Derivatives 
with Antileishmanial and Antitrypanosomal Activity,5 and New Series Being Studied.  
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The compounds were tested for in vitro activity against T. b. rhodesiense (strain 
STIB900) and on a standard panel of T. b. brucei lines (s427, TbAT1-KO, and TbB48) 
with decreasing sensitivity to most diamidine and arsenic-based drugs due to loss of 
specific drug transporters (see experimental section for details).7, 8 This is important 
because, like diamidines, most of the compounds described here are dications. In fact, 
the drug transporters may contribute positively to the selectivity of the compounds 
under development or, conversely, be a cause of drug resistance.9 Resistance to first line 
diamidines such as diminazene aceturate is linked to loss of these transporters10 and 
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represents a genuine threat to the treatability of trypanosomiasis.2 Thus, it is essential to 
ascertain that no cross-resistance between new compounds and existing therapy will 
arise. In addition, we established the dynamics of the action of phosphonium salts on 
trypanosomes: trypanocidal or trypanostatic; fast action or slow; minimum time of 
exposure etc. Finally, we sought to understand the SAR behind this class of 
phosphonium compounds by performing a CoMFA analysis.  
 
Results 
 Chemistry. The synthesis of the target compounds is based on the nucleophilic 
substitution of a (bis)halogenated precursor (i.e. linker) with a trisubstituted phosphine 
giving rise to the corresponding phosphonium salts (Scheme 1). Hence, the 
(bis)halogenated precursors must hold the different structural characteristics (i.e. linker 
type, linker length, number of cations, type of counterion) one wants to introduce in the 
lead structure.  
The different halogenated linkers were synthetized as shown in Scheme 2. The 4,4’-
bisbromomethyl linkers 1a,6 1b,11 1d,12 and 1e13 were synthesized by N-
bromosuccinimide (NBS) bromination of the 4,4’-dimethylphenyl precursors as 
previously reported. The linkers 1c and 2c were commercially available. The 4,4’-
bischloromethyl linker 3a was obtained by reaction of the corresponding 4,4’-
bisbromomethyl linker 1a with BiCl3 in anhydrous 1,2-dichloroethane.
14 The 
diphenylethane (10f, 12f) and diphenylpropane (11g, 13g) linkers were synthesized as 
shown in Scheme 2. Friedel-Crafts acylation of diphenylethane and diphenylpropane 
(oxalyl chloride/AlCl3) followed by decarbonylation in refluxing chlorobenzene gave 4 
and 5,15 respectively. The acyl chlorides were stirred in methanol at room temperature 
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to yield the methyl esters 6 and 7 quantitatively. Lithium aluminium hydride reduction 
of 6 and 7 gave excellent yields of the diols 8 and 9. These were converted to the 
dibromide (10f, 11g) and dichloride (12f, 13g) using thionyl bromide and thionyl 
chloride, respectively. The synthesis of the 4,4’-bis(2-chloroethylphenyl) linkers 16f 
and 17g started with Friedel-Crafts acylation of diphenylethane and diphenylpropane 
with chloroacetylchloride/AlCl3. Reduction of 14 and 15 with triethylsilane in 
trifluoroacetic acid yielded the expected products 16f and 17g, respectively.  
 
Scheme 1.
a Synthesis of the Phosphonium Salt Derivativesb 
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a Reagents and conditions. (i) R1R2R3P (excess), DMF or toluene, ∆. b See Tables 1–4 
for substituents pattern. 
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The bisphosphonium salts 18–53(a–e) were synthesized in good yields by reaction of 
the corresponding 4,4’-bischloromethyl- (3a, 12f, 13g), 4,4’-bisbromomethyl- (1a–1e, 
10f, 11g), or 4,4’-bischloroethyl linker (16f, 17g) with an excess of commercially 
available trisubstituted phosphine in anhydrous DMF at 100 ºC (150 ºC for 16f and 17g) 
(Scheme 1). The monophosphonium salts 54, 55, 56a–63a, and 56c–57c were prepared 
in the same way from 4-chloromethyltoluene, 4-bromomethyltoluene, 4-
bromomethylbenzophenone (2a), and 1-bromomethyl-4-phenoxybenzene (2c), 
respectively. A lower reaction temperature (50 ºC) was used with bis- and tris-2-
methoxyphenylphosphine (42a, 43a–c, and 61a) to avoid the formation of several by-
products. The salts were isolated by crystallization from the reaction mixture or by 
semi-preparative HPLC-MS for 64 and 65. Compounds 18a–24a, 26a, 28a–32a, 36a–
38a, 48a, and 49a were synthesized as reported earlier.5 
 
Scheme 2.
a Synthesis of the Linkers. 
 
a Reagents and conditions. (i) NBS, tBuOOH, CCl4, reflux, 20–52%; (ii) BiCl3, 1,2-
dichloroethane, ∆, 60–72%; (iii) 1) oxalyl chloride, AlCl3, CH2Cl2, -15 ºC, 5h; 2) 
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chlorobenzene, reflux, 5h, 80–84%; (iv) MeOH, rt, quantitative; (v) LiAlH4, THF, 
reflux, 18h, 90–94%; (vi) thionyl bromide, CH2Cl2, rt, 2h, 82–95%; (vii) thionyl 
chloride, CH2Cl2, rt, 2h, 68–97%; (viii) Et3SiH, CF3CO2H, 0 ºC → 45 ºC→ rt, 61–90%; 
(ix) ClCOCH2Cl, AlCl3, CH2Cl2, reflux, 3h, 94%; 
 
 In Vitro Antitrypanosomal Activity. The new compounds were tested for in vitro 
activity against T. b. rhodesiense (strain STIB900) and a standard panel of 
Trypanosoma brucei lines (s427, TbAT1-KO, and T. b. B48) with decreasing sensitivity 
to diamidine drugs. It should be noted that the small differences in phosphonium 
compounds EC50 values observed between T. b. rhodesiense STIB900 and T. b. brucei  
s427 are most probably due to the slightly different assay procedures used in the two 
laboratories involved in this work.16 Alternatively, they could reflect the minor 
biochemical differences between the two strains used. 
 In general, compounds with three short alkyl substituents (Me, Et, or Pr) on the 
phosphonium cations were poorly active against both trypanosome species (EC50 ≥ 10 
µM), whatever the linker was (Table 1: entries 1–6; Table 4: entries 7, 9). The activity 
was enhanced with the increase in chain length (n-octyl ≈ n-hexyl > c-hexyl ≈ n-pentyl 
> n-Bu > i-Bu) reaching a maximum for 6- to 8-carbon substituents (Table 1, entries 7–
18). Replacement of the alkyl substituents with phenyl rings increased the activity in the 
order: R1, R2, R3 = alkyl < (R1, R2 = alkyl; R3 = Ph) < (R1 = alkyl; R2, R3 = Ph) (Table 
1: entries 19–32).  
Since the best activities and selectivities were obtained with phenyl substituents, we 
decided to study whether the presence of substituents on the aromatic ring would 
influence the antitrypanosomal activity. As shown in Table 2, the best results were 
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obtained with the 4-Me substituted phenyl rings (entries 16–25). Substitution pattern for 
the phenyl ring, in order of decreasing activity, was: 4-Me > 3-Me > H and 2-OMe > 4-
OMe > 4-Cl ≈ 4-F > 4-CF3. Within this series, the order of decreasing activity as a 
function of the linker was: O ≈ (CH2)3 > (CH2)2 ≈ CH2 > CO > SO2 ≈ NAc.  
Bioisosteric replacement of the phenyl substituents of the phosphonium cation by 2-
thienyl groups (Table 3, entries 1,2) or 1-naphthyl substituents (Table 3, entries 10–12) 
maintained the activity. On the contrary, the introduction of an oxygenated (2-furanyl) 
or amino (2-pyridyl) heterocycle (entries 3, 4) was detrimental to the activity, 
presumably because these are more polar and the substituents can engage in hydrogen 
bonds. Likewise, the replacement of one phenyl susbtitutent by a more polar 
phenylsulphonate or pentafluorophenyl ring abolished the trypanocidal activity (Table 
3, entries 6–9).  
Interestingly, removal of one of the phosphonium cations did not reduce the 
antitrypanosomal activity (Table 4). On the contrary, lower EC50 values were observed 
for 56a, 56c, 57c, 59a, and 62a compared with their bisphosphonium salt analogues 
(45a, 45c, 46c, 38a, and 25a, respectively). Regarding the substituents pattern, the same 
SAR as for the bisphosphonium analogues was observed (i.e., p-tolyl > m-tolyl and n-
hex > i-Bu >> Et). In this series, replacement of the carbonyl group by an oxygen linker 
enhanced the in vitro activity 20 to 40-fold against T. b. rhodesiense (compare 56a vs 
56c, 57a vs 57c). The diphenylether analogues 56c and 57c were the most active 
compounds of all the series with EC50 values in the low nanomolar range against wild 
type and resistant T. b. brucei lines (Table 4, entries 4 and 6), respectively. Despite their 
submicromolar and low micromolar cytotoxicity towards L6-cells and HEK-cells, 
respectively, both compounds still have a reasonable therapeutic window with a 
 10 
selectivity index (SI) vs L6-cells of 131 and 62, and of 1145 and 876 vs HEK-cells, 
respectively. 
As far as the counterion is concerned, no significant difference in in vitro activity was 
observed between the bromide and the chloride salt of the compounds (Table 2, entries 
16–22). In addition, a longer linker (i.e., ethylene instead of methylene linker) between 
the phosphonium cation and the central diphenyl core hardly affected the activity as 
shown by the nanomolar EC50s of compounds 65 (73 nM vs 63 nM for 45g) and 64 (27 
nM vs 50 nM for 45f) (Table 5). 
In most cases, the compounds displayed an acceptable selectivity index towards HEK 
cells (>100). However, higher cytotoxicity was found with L6-cells, indicating a notable 
difference in susceptibility to phosphonium compounds between the two cell lines.  
 
Cross-resistance and drug transport. Importantly, EC50 values were found to be 
statistically identical for the s427, TbAT1-KO and B48 strains in all cases (Student t-
test; P>0.05). This indicates that there is no cross resistance between the phosphonium 
cations and the crucial diamidine and melaminophenyl arsenical classes of trypanocides. 
However, the resazurin assay employed to generate EC50 values provides a single 
reading after an initial 48-h incubation period with test compound followed by a further 
24 h in the additional presence of the dye. While this allows for high throughput, 
reproducible EC50s, it gives no information on how speedily the compounds act on the 
cells. The relationship between drug concentration and minimal exposure time is 
important as it has major implications for potential drug development: should the drug 
be required to be present in circulation for 48 h at a concentration >EC90 this would 
inevitably require a far higher dosage, and more frequent administration, than achieving  
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such a dose for 2 h. We thus conducted a series of experiments to assess differential 
action on the cell lines by a small selection of phosphonium salts. We used incubations 
with the viability reporter dye propidium iodide (PI), which gives a fluorescent signal 
upon cell entry and binding to nucleic acid.17 Figure 1 shows the effects on cellular 
integrity by 24a, recorded in real-time for a period of >8 h. This revealed that, for all 
three strains only concentrations ≥3.3 µM affected viability over the course of the 
experiment, despite EC50 values ≤0.20 µM. Yet, the speed at which the cell membrane 
integrity was compromised appeared to be slightly less in the diamidine resistant strains. 
Similar observations were made for 25b, 25c, 26a, 35a, 36a, 38a, 43a, 43c, 45d, 45e, 
47a, and 55 (see online Supporting Information).  
  
 12 
 
Figure 1. Real Time Monitoring of the Effects of 24a on Various Strains of T. b. 
brucei. The experiment was conducted with 5×105 cells/well in a 96-well format, with 
200 µl/well of HMI-9 medium containing 10% FBS and 9 µM PI. Fluorescence was 
determined every 2 minutes for a total of 250 cycles; fluorescence was read using 
544/620 nm filters for excitation and emission, respectively. Fluorescence values were 
determined in parallel for all three strains, using a single 96-well plate incubated in a 
Fluostar Optima fluorimeter at 37 °C and 5% CO2. The slow increase in fluorescence in 
drug-free controls is attributable to the slow entry of PI into live trypanosomes.17 
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Given the very similar sensitivities, it must be deemed highly unlikely that the cellular 
entry of these cations depends critically on either of the two diamidine transporters (i.e., 
TbAT1/P2 aminopurine transporter and the High Affinity Pentamidine Transporter, 
HAPT1) that are known to be, by their absence, the cause of resistance in the strain 
B48.8, 18 We can speculate that, unlike diamidines, the positive charge(s) of the 
(bis)phosphonium compounds are highly dispersed and shielded by hydrophobic 
substituents, allowing trans-membrane diffusion at an appreciable rate.19 It is noted, in 
this context, that the anti-parasitic activity seems to be proportionate with the level of 
shielding, with methyl and ethyl substituents having virtually no effect (18a, 19a). Yet, 
some of the phosphonium compounds, such as 24a and 45e were good inhibitors of the 
diamidines transporters, especially of the Low Affinity Pentamidine Transporter 
(LAPT1),20 for which most of the compounds displayed higher affinity than the original 
substrate pentamidine (Table 6). As there was, however, no correlation between 
inhibition of the transporters and the antiparasitic activity, we conclude that the activity 
is not dependent on entry through any of the known drug transporters, with diffusion 
being the likely route of entry. 
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Table 1. Antitrypanosomal Activity of Bisphosphonium Salts having Aliphatic and Phenyl Substituents.  
 
Entry Cmpd L R1 R2 R3 T. b. rhod.
a Cytox. L6b T. b. brucei WTc TbAT1-KOd RFe T.b. B48f RFe Cytox. HEKg SIh 
      EC50 (µM) (Selectivity index)i 
 
Melarsoprol 
Podophyllotoxin 
Pentamidine 
Diminazene 
    
0.0075 
 
 
 
 
0.012 
 
 
 
 
0.008 ± 0.002 
0.517 ± 0.132 
 
 
0.009 ± 0.003 
2.39 ± 0.84 
 
 
1.1 
4.6 
 
 
0.567 ± 0.086 
2.617 ± 0.714 
 
 
70.9 
5.1 
  
1 18a CO Me Me Me 127 >173 >100 >100  >100  ndj  
2 19a CO Et Et Et 77.8 >149 >100 >100  >100  >300  
3 19b CH2 Et Et Et 18.7 48.3 21.5 ± 0.3 18.5 ± 0.4 0.9 19.3 ± 0.2 0.9 >300 >14 
4 19c O Et Et Et 31.9 101.6 36.5 ± 3.5 34.9 ± 0.2 1.0 36.6 ± 0.6 1.0 >300 >8 
5 20a CO n-Pr n-Pr n-Pr 8.5 >130 19.73 ± 4.11 27.15 ± 3.82 1.4 31.32 ± 4.15 1.6 nd  
6 21a CO iPr iPr iPr 9.6 >130 20.55 ± 5.19 33.41 ± 6.20 1.6 38.82 ± 6.41 1.9 nd  
7 22a CO n-Bu n-Bu n-Bu 0.355 (315) 111.7 0.48 ± 0.11 1.32 ± 0.46 2.7 1.63 ± 0.46 3.4 >300 >620 
8 23a CO iBu iBu iBu 1.46 >116 2.62 ± 0.69 8.34 ± 3.08 3.2 6.30 ± 1.39 2.4 >300 >110 
9 23b CH2 
iBu iBu iBu 0.326 (141) 45.9 0.70 ± 0.03 0.88 ± 0.10 1.3 0.88 ± 0.06 1.3 >300 >429 
10 23c O iBu iBu iBu 1.62 51.1 0.59 ± 0.06 0.80 ± 0.10 1.3 1.06 ± 0.34 1.8 >300 >507 
11 23d SO2 
iBu iBu iBu 6.31 >111 16.7 ± 0.5 13.6 ± 2.2 0.8 13.3 ± 1.6 0.8 nd  
12 23e NAc iBu iBu iBu 11.44 >112 nd nd  nd  nd  
13 24a CO n-pentyl n-pentyl n-pentyl 0.289 (30) 8.7 0.20 ± 0.03 0.17 ± 0.01 0.8 0.18 ± 0.01 0.9 66.8 ± 4.9 338 
14 25a CO n-hex n-hex n-hex 0.112 (10) 1.11 0.038 ± 0.001 0.047 ± 0.007 1.2 0.035 ± 0.003 0.9 16.6 ± 0.7 438 
15 25b CH2 n-hex n-hex n-hex 0.180 (5) 0.964 0.033 ± 0.006 0.033 ± 0.005 1.0 0.039 ± 0.002 1.2 18.1 ± 2.6 543 
16 25c O n-hex n-hex n-hex 0.109 (9) 1.03 0.037 ± 0.004 0.045 ± 0.005 1.2 0.041 ± 0.002 1.1 22.1 ± 1.1 593 
17 26a CO c-hex c-hex c-hex 0.197 (166) 32.7 0.14 ± 0.03 0.23 ± 0.05 1.6 0.25 ± 0.04 1.8 >300 >2100 
18 27a CO n-octyl n-octyl n-octyl 0.22 (5) 1.0 0.042 ± 0.002 0.061 ± 0.001 1.4 0.045 ± 0.001 1.1 27.0 ± 1.4 639 
19 28a CO Me Me Ph 8.8 >139 19.17 ± 7.17 28.77 ± 5.62 1.5 24.55 ± 4.75 1.3 nd  
20 28b CH2 Me Me Ph 2.586 >142 5.45 ± 1.09 4.60 ± 0.80 0.8 3.84 ± 1.19 0.7 >300 >55 
21 28c O Me Me Ph 3.827 84.5 7.22 ± 0.16 6.52 ± 0.39 0.9 6.15 ± 0.89 0.9 >300 >40 
22 28f (CH2)2 Me Me Ph 1.20 (40) 48.6 2.59 ± 0.64 2.62 ± 0.16 1.0 1.8 ± 0.58 0.5 >300 >110 
23 28g (CH2)3 Me Me Ph 1.22 (49) 59.5 1.27 ± 0.33 1.37 ± 0.11 1.1 1.09 ± 0.38 0.9 >300 >230 
24 29a CO Et Et Ph 2.9 >128 8.59 ± 2.16 17.75 ± 2.03 2.1 15.17 ± 3.72 1.8 >300 >35 
25 30a CO c-hex c-hex Ph 0.32 (72) 22.9 0.24 ± 0.03 0.26 ± 0.04 1.1 0.29 ± 0.03 1.2 >300 >1270 
26 31a CO Me Ph Ph 0.656 (177) 115.9 1.53 ± 0.38 2.08 ± 0.63 1.4 2.05 ± 0.38 1.3 >300 >200 
27 32a CO Et Ph Ph 0.554 (>204) >113 0.97 ± 0.27 2.10 ± 0.54 2.2 1.76 ± 0.30 1.8 >300 >300 
28 33b CH2 n-Pr Ph Ph 0.799 (4.1) 3.27 0.373 ± 0.003 0.40 ± 0.01 1.1 0.43 ± 0.08 1.1 >300 >800 
29 33c O n-Pr Ph Ph 0.567 (5) 2.9 0.25± 0.03 0.28 ± 0.01 1.1 0.3 ± 0.01 1.2 233 ± 31 914 
30 34b CH2 
iPr Ph Ph 0.534 (6.4) 3.44 0.44 ± 0.04 0.40 ± 0.03 0.9 0.43 ± 0.09 1.0 >300 >680 
31 34c O iPr Ph Ph 0.585 (8.6) 5.0 0.33 ± 0.02 0.33 ± 0.01 1.0 0.33 ± 0.01 1.0 >300 >900 
32 35a CO c-hex Ph Ph 0.43 (155) 65.8 0.30 ± 0.03 0.41 ± 0.01 1.4 0.33 ± 0.03 1.1 >300 >1000 
a T. b. rhodesiense STIB900 trypomastigotes; b Rat skeletal myoblast L-6 cells; c T. b. brucei s427 
trypomastigotes; d T. b. brucei knockout strain lacking a functional P2-transporter and resistant to 
diminazene aceturate18; e Resistance factor compared to WT; f The B48 strain is a mutant derived from the 
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TbAT1-KO strain with a nonfunctional High Affinity Pentamidine transporter (HAPT). This strain is 
resistant to diminazene, pentamidine and melaminophenyl arsenicals8; g Human Embryonic Kidney (HEK) 
cells; h Selectivity index = [EC50 (HEK cells) / EC50 (T. b .brucei WT)]; 
i Selectivity index = [EC50 (L6-
cells) / EC50 (T. b. rhodesiense)]; 
j Not determined. 
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Table 2. Antitrypanosomal Activity of Bisphosphonium Salts having Substituted Phenyl Substituentsa  
 
Entry Cmpd L R1 R2 R3 T. b. rhod.
a Cytox. L6b T. b. brucei WTc TbAT1-KOd RFe T.b. B48f RF Cytox. HEKg SIh 
      EC50 (µM) (Selectivity index)i 
1 36a CO H H H 0.260 (282) 73.3 0.24 ± 0.07 0.36 ± 0.07 1.5 0.38 ± 0.06 1.6 >300 >1250 
2 37a CO H H 2-Me 0.16 (88) 14.0 0.20 ± 0.01 0.24 ± 0.03 1.2 0.22 ± 0.02 1.1 214.3 ± 9.5 1098 
3 38a CO H H 4-Me 0.26 (62) 16.3 0.180 ± 0.002 0.182 ± 0.006 1.0 0.183 ± 0.005 1.0 261.3 ± 24.3 1449 
4 38b CH2 H H 4-Me 0.200 (22) 4.47 0.24 ± 0.04 0.19 ± 0.03 0.8 0.18 ± 0.02 0.7 >300 >1250 
5 38c O H H 4-Me 0.142 (23) 3.34 0.082 ± 0.014 0.077 ± 0.002 0.9 0.064 ± 0.009 0.8 240.3 ± 6.7 2930 
6 39a CO 4-Cl 4-Cl 4-Cl 0.41 (18) 7.2 0.94 ± 0.14 1.37 ± 0.02 1.5 0.95 ± 0.13 1.0 63 ± 8 67 
7 40a CO 4-F 4-F 4-F 0.45 (172) 77.4 0.85 ± 0.17 2.10 ± 0.03 2.5 1.24 ± 0.14 1.5 >300 >350 
8 41a CO 4-OMe 4-OMe 4-OMe 0.29 (40) 11.8 0.32 ± 0.07 0.52 ± 0.02 1.6 0.23 ± 0.04 0.7 172 ± 7 529 
9 42a CO 2-OMe 2-OMe H 0.23 (28) 6.4 0.24 ± 0.04 0.32 ± 0.02 1.3 0.19 ± 0.04 0.8 107 ± 15 438 
10 43a CO 2-OMe 2-OMe 2-OMe 0.20 (45) 9.0 0.11 ± 0.02 0.16 ± 0.01 1.5 0.08 ± 0.02 0.7 131 ± 17 1175 
11 43b CH2 2-OMe 2-OMe 2-OMe 0.209 (5) 1.08 0.080 ± 0.004 0.074 ± 0.003 0.9 0.066 ± 0.002 0.8 204 ± 13 2561 
12 43c O 2-OMe 2-OMe 2-OMe 0.153 (8) 1.27 0.056 ± 0.011 0.057 ± 0.008 1.0 0.045 ± 0.004 0.8 141 ± 5 2518 
13 44a CO 4-CF3 4-CF3 4-CF3 16.4 25.0 5.05 ± 1.84 8.51 ± 1.98 1.7 2.73 ± 0.76 0.5 >300 >60 
14 44b CH2 4-CF3 4-CF3 4-CF3 1.72 7.52 0.23 ± 0.06 0.37 ± 0.09 1.6 0.28 ± 0.04 1.2 77.1 ± 8.6 338 
15 44c O 4-CF3 4-CF3 4-CF3 5.26 9.93 0.24 ± 0.06 0.32 ± 0.05 1.3 0.28 ± 0.05 1.2 174 ± 23 723 
16 45a CO 4-Me 4-Me 4-Me 0.22 (49) 10.8 0.11 ± 0.02 0.018 ± 0.01 1.6 0.09 ± 0.02 0.8 141 ± 10 1266 
17 45a (Cl- salt) CO 4-Me 4-Me 4-Me 0.084 (14.5) 1.22 0.094 ± 0.023 0.065 ± 0.002 0.7 0.073 ± 0.025 0.8 24 ± 1.2 254 
18 45b CH2 4-Me 4-Me 4-Me 0.099 (24) 2.33 0.080 ± 0.002 0.080 ± 0.003 1.0 0.074 ± 0.001 0.9 233 ± 14 2905 
19 45f (CH2)2 4-Me 4-Me 4-Me 0.084 (7.8) 0.656 0.15 ± 0.06 0.15 ± 0.02 1.0 0.15 ± 0.06 1.0 32.4 ± 2.4 213 
20 45f (Cl- salt) (CH2)2 4-Me 4-Me 4-Me 0.050 (33.8) 1.69 0.058 ± 0.026 0.030 ± 0.008 0.5 0.045 ± 0.018 0.8 23.3 ± 0.4 404 
21 45g (CH2)3 4-Me 4-Me 4-Me 0.081 (22) 1.80 0.029 ± 0.005 0.049 ± 0.007 1.7 0.053 ± 0.003 1.8 25.8 ± 1.7 897 
22 45g (Cl- salt) (CH2)3 4-Me 4-Me 4-Me 0.063 (27.3) 1.72 0.100 ± 0.034 0.066 ± 0.005 0.7 0.062 ±0.004 0.6 12.7 ± 0.5 127 
23 45c O 4-Me 4-Me 4-Me 0.170 (14) 2.34 0.024 ± 0.005 0.025 ± 0.004 1.0 0.021 ± 0.001 0.8 85.7 ± 6.4 3567 
24 45d SO2 4-Me 4-Me 4-Me 0.173 (127) 22.0 0.23 ± 0.01 0.253 ± 0.002 1.1 0.27 ± 0.01 1.2 >300 >1300 
25 45e NAc 4-Me 4-Me 4-Me 0.159 (137) 21.8 0.32 ± 0.01 0.30 ± 0.01 0.9 0.29 ± 0.01 0.9 >300 >930 
26 46b CH2 3-Me 3-Me 3-Me 0.231 (4) 0.939 0.14 ± 0.02 0.14 ± 0.01 1.0 0.13 ± 0.02 0.9 72.6 ± 7.1 524 
27 46c O 3-Me 3-Me 3-Me 0.488 (1.9) 0.942 0.057 ± 0.013 0.043 ± 0.004 0.7 0.088 ± 0.024 1.5 45.4 ± 12.4 792 
a See Table 1 for footnotes and reference drugs EC50 values. 
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Table 3. Antitrypanosomal Activity of Bisphosphonium Salts having Aryl Groups or Heterocycle 
Substituentsa  
 
Entry Cmpd L Ar1 Ar2 Ar3 T. b. rhod.
a Cytox. L6b T. b. brucei WTc TbAT1-KOd RFe T.b. B48f RFe Cytox. HEKg SIh 
      EC50 (µM) (Selectivity index)i 
1 36a CO Ph Ph Ph 0.260 (282) 73.3 0.24 ± 0.07 0.36 ± 0.07 1.5 0.38 ± 0.06 1.6 >300 >1250 
2 47a CO 2-thienyl 2-thienyl 2-thienyl 0.29 (58) 16.6 0.33 ± 0.06 0.52 ± 0.03 1.6 0.33 ± 0.05 1.0 260 ± 21 785 
3 48a CO 2-furanyl 2-furanyl 2-furanyl 13.81 86.0 36.9 ± 1.2 33.8 ± 1.2 0.9 21.7 ± 1.2 0.6 ndj  
4 49a CO Ph Ph 2-pyridyl 0.607 (24) 14.6 0.70 ± 0.24 1.43 ± 0.41 2.0 1.33 ± 0.26 1.9 >300 >400 
5 50a CO Bn Ph Ph 0.48 (67) 32.0 0.81 ± 0.12 1.02 ± 0.02 1.3 1.03 ± 0.22 1.3 >300 >370 
6 51b CH2 Ph Ph C6F5 16.0 P
b 2.68 ± 0.05 3.79 ± 0.09 1.4 2.74 ± 0.02 1.0 >300 >110 
7 51c O Ph Ph C6F5 12.8 5.35 23.2 ± 3.1 9.9 ± 1.9 0.4 6.68 ± 1.65 0.3 >300 >10 
8 52b CH2 Ph Ph 3-(SO3Na)Ph > 92 > 92 >100 >100  >100  >300  
9 52c O Ph Ph 3-(SO3Na)Ph > 92 90.5 >100 >100  >100  >300  
10 53a CO 1-naphthyl 1-naphthyl 1-naphthyl 0.40 (12) 4.9 0.18 ± 0.04 0.339 ± 0.005 1.8 0.18 ± 0.04 1.0 92 ± 4.0 502 
11 53b CH2 1-naphthyl 1-naphthyl 1-naphthyl 0.299 (12) 3.43 0.14 ± 0.02 0.17 ± 0.04 1.3 0.14 ± 0.01 1.0 163 ± 19 1207 
12 53c O 1-naphthyl 1-naphthyl 1-naphthyl 0.384 (9) 3.45 0.16 ± 0.01 0.14 ± 0.01 0.9 0.128 ± 0.002 0.8 114 ±16 722 
a See Table 1 for footnotes and reference drugs EC50 values. 
b Precipitate in solution. 
Table 4. Antitrypanosomal Activity of Monophosphonium Saltsa 
  
Entry Cmpd L R1 R2 R3 T. b. rhod.
a Cytox. L6b T. b. brucei WTc TbAT1-KOd RFe T.b. B48f RFe Cytox. HEKg SIh 
      EC50 (µM) (Selectivity index)i 
1 54       0.216 (48) 10.4 0.023 ± 0.001 0.024 ± 0.002 1.0 0.023 ± 0.001 1.0 >300 >12500 
2 55     0.364 (35.5) 12.9 0.043 ± 0.001 0.033 ± 0.006 0.8 0.022 ± 0.000 0.5 >300 >7000 
3 56a CO 4-Me-Ph 4-Me-Ph 4-Me-Ph 0.081 (16.7) 1.35 0.064 ± 0.004 0.012 ± 0.002 0.2 0.011 ± 0.003 0.2 32.5 ± 3.6 505 
4 56c O 4-Me-Ph 4-Me-Ph 4-Me-Ph 0.002 (131) 0.263 0.015 ±0.002 0.013 ± 0.0006 0.8 0.010 ± 0.001 0.7 17.6 ± 1.2 1145 
5 57a CO 3-Me-Ph 3-Me-Ph 3-Me-Ph 0.274 (9.5) 2.61 0.17 ± 0.05 0.15 ± 0.03 0.8 0.11 ± 0.03 0.7 48.2 ± 2.4 281 
6 57c O 3-Me-Ph 3-Me-Ph 3-Me-Ph 0.014 (62) 0.870 0.028 ± 0.002 0.021 ± 0.002 0.8 0.017 ± 0.0003 0.6 24.5 ± 2.3 876 
7 58a CO iBu iBu iBu 4.48 >209 5.9 ± 0.7 6.1 ± 0.9 1.0 6.28 ± 0.85 1.1 >300 >50 
8 59a CO 4-Me-Ph Ph Ph 0.267 (29) 7.72 0.15 ± 0.03 0.15 ± 0.02 1.0 0.10 ± 0.01 0.7 76.8 ± 2.0 504 
9 60a CO Et Et Et > 254 >254 >100 >100  >100  >300  
10 61a CO 2-MeO-Ph 2-MeO-Ph 2-MeO-Ph 0.376 (10) 3.97 0.21 ± 0.05 0.22± 0.06 1.1 0.15 ± 0.03 0.7 63.2 ± 4.4 306 
11 62a CO n-hex n-hex n-hex 0.103 (15) 1.61 0.011 ± 0.004 0.008 ± 0.003 0.7 0.022 ± 0.011 1.9 13.4 ± 0.3 1198 
12 63a CO Me Me Ph 16.94 >241 42.7 ± 6.2 46.6 ± 2.3 1.1 45.8 ± 12.8 1.1 >300 >7 
a See Table 1 for footnotes and reference drugs EC50 values. 
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Table 5. Antitrypanosomal Activity of Phosphonium Salts with Ethylene Linkera 
 
Cmpd Salt form m n T. b. rhod.a Cytox. L6e T. b. brucei WTb TbAT1-KOc RF T.b. B48d RF Cytox. HEKf SIg 
    EC50 (µM) (Selectivity index)i 
45f Br- 2 1 0.084 (7.8) 0.656 0.15 ± 0.06 0.15 ± 0.02 1.0 0.15 ± 0.06 1.0 32.4 ± 2.4 213 
45g Br- 3 1 0.081 (22) 1.80 0.029 ± 0.005 0.049 ± 0.007 1.7 0.053 ± 0.003 1.8 25.8 ± 1.7 897 
64 Cl- 2 2 0.027 (40.3) 1.09 0.125 ± 0.027 0.094 ± 0.023 0.8 0.089 ± 0.017 0.7 12.8 ± 0.9 103 
65 Cl- 3 2 0.073 (8.8) 0.645 0.077 ± 0.022 0.043 ± 0.009 0.6 0.048 ± 0.007 0.6 5.6 ± 0.2 73 
a See Table 1 for footnotes and reference drugs EC50 values. 
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Table 6. Affinity of Selected Phosphonium Compounds on the HAPT1 and LAPT1 
Diamidine Transporters of T. b. brucei. 
Compound Ki value, HAPT1 
(µM, ± SE) 
Ki value, LAPT1 
(µM, ± SE) 
Pentamidinea 0.036 ± 0.006 56.2 ± 8.3 
18a >250 >250 
24a 5.2 ± 0.9 2.2 ± 0.4 
25a NDb 25 ± 6 
25b ND 9.5 ± 0.5 
25c 53 ± 13 7.2 ± 4.0 
26a ND 39 ± 7 
35a ND 19 ± 6 
36a ND 49 ± 6 
38b ND 20 ± 4 
45e 9.2 ± 1.3 3.6 ± 0.4 
55 ND 25 ± 11 
Experiments were performed in triplicate, and on at least three separate occasions, as 
described in references [8, 20]. a Taken from ref [20]; b ND, not determined. 
 
Characterisation of the action of phosphonium salts on T. b. brucei. Figure 1 
indicated that 24a only affected cellular viability during an 8-h experiment at 
concentrations >15-fold its EC50 value. In fact, numerous additional bisphosphonium 
salts were tested over 8 h on T. b. brucei s427 and typically affected parasite viability 
only at concentrations 70 – 120 × EC50 (see Supporting Information). The only 
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exception was 55, with only concentrations >700 × EC50 affecting parasite survival 
within this time frame. This indicates that mono-phosphonium salts may affect 
trypanosomes more slowly than the corresponding dications, probably because the 
single positive charge provides less driving force to cross inside-negative membranes.  
In fact, previous studies by Ross et al.19 have shown that lipophilic 
triphenylphosphonium dications are accumulated into mitochondria to a greater extent 
than their monocationic counterpart.  
It is thus clear that, while monophosphonium and bisphosphonium compounds act 
potently on trypanosomes, their effect on cellular integrity is relatively slow. In order to 
assess the timing of the antitrypanosomal effect of phosphonium compounds we 
conducted manual cell counts on cultures incubated with various concentrations of test 
compound. We found that growth rates of T. b. brucei bloodstream forms were initially 
reduced upon incubation with phosphonium salts at concentrations of EC50 or slightly 
over, but typically recovered after 36 h; only at concentrations ≥ 2 × EC50 did the cells 
not recover from the initial growth inhibition and started to die after 12 h (Figure 2A).  
Although trypanosomes died only slowly on incubation with phosphonium compounds, 
only a relatively short exposure time was required. Figure 2B shows that removal of 25c 
after a mere 30 min of incubation allowed for only very limited resumption of growth, 
reaching a maximum density of 9.4×105 cells/ml at 48h (i.e., 15% of the drug-free 
control). Removal of drug after 4 h did not lead to any resumption of growth at all, and 
the trypanosome population slowly dwindled over the next 44 h. Continuous exposure 
to the drug resulted in sterilisation of the culture after approximately 30 h. Highly 
similar results were obtained with a number of other compounds including 25b and 45c.  
 21 
 
Figure 2. Effect of 25c on Cultures of T. b. brucei Bloodstream Forms. Cultures in the 
presence or absence of various concentrations of 25c were set up at a concentration of 
105 cells/ml. Microscopic cell counts were performed in triplicate using a 
haemocytometer and average values are shown.  
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A. Cells were incubated in the continuous presence of 0.05 µM (□), 0.25 µM (▲), or 1 
µM 25c (○), or no compound (control, ●). Inset: same data but showing the full growth 
over 48 h on a different scale. 
B. Reversibility of growth inhibition by 0.25 µM 25c was determined by centrifugation 
1100 × g) after either 30 min (■,□) or 4 h (●,○) and replacement with drug-free fresh 
medium (closed symbols, solid lines) or fresh medium with 0.25 µM 25c (open 
symbols, dashed lines). A control culture (▲, no drug) reached a density of 6×106 
cells/ml after 48 h, as in panel A. 
 
CoMFA Models. In order to gain insights into the SAR of this class of phosphonium 
salts, we have derived two main CoMFA models based on the EC50 values for T. b. 
rhodesiense and T. b. brucei, respectively (Tables 1–5). Both models are, at the least, 
able to discriminate activities and they possess a moderate to high predictive power. 
Nevertheless our hypothesis that both endpoints have a similar behaviour is confirmed 
by the modelling step. The two models are so alike that explaining both in details 
becomes redundant, consistent with identical modes of action for these closely related 
species. Therefore we are presenting here only the T. b. brucei model. For further 
reading about the T. b. rhodesiense model see the Supporting Information. 
The training set (54 compounds) model statistics are fairly good: slope 0.8905, y 
intercept 0.0466, r2 0.891, F 99.7. Standard validations on the training set were 
conducted in several ways: Leave One Out using SAMPLS algorithm21 (SAMple-
distance Partial Least Squares), q2=0.43, 3 components Partial Least Squares (PLS) 
fitting; 10 groups Leave Several Out (LSO): q2=0.379, 3 components PLS fitting and 
bootstrapping: averaged r2 0.856 and averaged Standard Error (SE) was 0.343. Cross 
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validation values were not actually promising so some suspicions of over fitting arose. 
However the test set statistics (Figure 3), a set never used in the modeling step, refuted 
this point. For T. b. brucei (pEC50 exp. vs. pEC50 theor.), the model statistics are as 
follows: slope 0.7531, intercept 0.0117 and r2 0.744 (excluding outliers), or r2 0.67 
(including outliers). Such values fulfill the rules for predictive models proposed by 
Tropsha et al.22 (i.e. r0
2 0.743), and can be considered as clearly predictive. 
 
Figure 3. CoMFA Model for T. b. brucei. Plot of -log10[EC50 (µM)]experimental vs. -
log10[EC50(µM)]predicted for T. b. brucei WT. Outliers are not shown; model statistics are 
commented in the text.  
 
Leaving aside the good behavior of this model, a number of outliers were found within 
the test set: 48a, 52b, 52c and 63a. Compound 48a can be considered as an outlier due 
to its similar structure to 47a, a rather active compound, whilst no other related 
structures were included. This fact clearly biased the model to predict a higher activity 
than it actually has. However, 48a was still predicted as inactive.  
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52b and 52c were not included in the modeling step because their activities were not 
determined at the time of generating this model. These compounds are outliers because 
they are the only ones with neutral charge (i.e., presence of the 3-phenylsulphonate 
substituent) and no compound alike was included in the model. It should be noted that 
the counterions are not taken into account to generate the CoMFA models (see 
experimental part). Finally, 63a has clearly a lower activity than would be expected 
based on our model. This is probably due to the lack of lipophilic shielding around the 
phosphonium cation, reducing membrane permeation. For quantitative information see 
Table S2 in Supporting Information. 
CoMFA fields derived from this model denote that the steric component is rather 
selective (Figure 4). Indeed the steric contribution to the CoMFA is 0.641. Bulk is 
strictly forbidden around the whole molecule except upon special positions on the 
phosphorous substituent. Such positions coincide with para and meta substitutions on 6-
membered aromatic rings which can also be easily occupied by long enough aliphatic 
chains. This fact explains why aliphatic chains are not active up to a certain number of 
carbons (C ≤ 4); molecules with such small substituent do not fill the preferred volume 
(sse Figure 4A, compound 18a shown in blue) whilst they do not offer the essential 
lipophilic shielding to the phosphonium cation. 
One issue derived from the good activities obtained for monocations is a remarkable 
loss of symmetry on the steric fields. While one end of the molecule is nearly 
surrounded by sterically unfavorable fields the distal end is virtually the opposite. Such 
assumption is coherent with the submicromolar activities found for dications with 
symmetric aromatic substitution (e. g. see Figure 4A, compound 41a shown in red). 
Here the favorable effect of bulk in one molecular end is compensated somehow by the 
same unfavorable bulk in the distal end. It is indeed the flexibility of aliphatic chains, 
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able to avoid the restricted areas, the predominant effect on the nanomolar activities of 
compounds such as 25a–c (see Figure 4A, compound 25a showed in magenta) 
compared with 26a.  
Electrostatic fields show that positive charge dispersion over the whole molecule favors 
the activity as we previously supposed. Here we see again a loss on the symmetry on the 
fields where a bit of negatively charged substituent, near the phosphonium (e.g., OMe, 
F…) and close to the more sterically impeded area, would favor the activity of these 
compounds. This is the case of compounds 43b and 43c bearing 2-methoxyphenyl 
substituents  (see Figure 4B). In such cases this is the predominant effect confronted 
with the mere bulk offered by only aromatic substitution, such as in 50a. Surprisingly 
enough there is no other negative favorable area in the model. This is combined with a 
huge dispersion of the positive charge upon the molecule even surrounding the negative 
surfaces. We can deduce then a  minor influence of localized electrostatic interactions, 
such as hydrogen bonds, with the phosphonium salts activities.  
 
A 
A 
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Figure 4. Steric and Electrostatic CoMFA Fields for T. b. brucei. A) Steric fields: 
regions where increasing the volume of the molecule favors antitrypanosomal activity 
are green; regions where increasing the volume decreases antitrypanosomal activity are 
yellow. Compounds 18a (blue),  25a (magenta), and 41a (red) are shown. B) 
Electrostatics field contours: indicate an increase of anti-T. brucei activity with 
increasing positive (blue) and negative (red) charge, respectively. Compound 43c is 
shown. 
 
Discussion 
Phosphonium salts bearing hydrophobic substituents are lipophilic cations with a 
delocalized charge. This affords specific properties to these molecules such as the 
capacity to cross biological membranes driven by electrical potential. Thus, they tend to 
accumulate in organelles with high membrane potential such as mitochondria.23 In 
Leishmania, several of the benzophenone-derived bisphosphonium salts reported here 
B 
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were found to target mitochondria of the parasite, a key to their leishmanicidal action.5 
Ongoing studies on its mechanism of action in T. brucei point also to a mitochondrial 
target; for instance, phosphonium compounds strongly affected the mitochondrial 
membrane potential (unpublished results). 
Interestingly, the SAR of the series of compounds presented here shows some 
similarities with the SAR against Leishmania. For instance, for compounds with 
homoalkyl groups, optimum activity was observed with 5- to 8-carbons, independently 
of the linker (Tables 1 and 4). In the same way, the combination of two phenyl groups 
and one alkyl substituent was enough to get submicromolar activity whereas the 
combination of one phenyl group and two short alkyl substituents (Me, Et) led to 
micromolar EC50. These observations are clearly supported by the CoMFA models 
which show that a minimum bulk around the phosphonium cations is favourable to the 
activity but this volume is also limited in size. 
From these data, it is clear that a substantial level of lipophilic shielding around the 
phosphonium cation(s) is necessary to get high levels of activity against Trypanosoma 
and Leishmania species, presumably by increasing membrane permeation. No 
correlation was found between the antiparasitic activity and inhibition of the known T. 
brucei drug transporters (P2, HAPT1, and LAPT1). Although some bis-phosphonium 
compounds displayed surprisingly high affinity for the HAPT1 and LAPT1 transporters, 
most of the bis-phosphonium compounds would be considered too large to be a 
substrate (as opposed to be inhibitor) of such transporters (e.g., molecular weights range 
between 800 and 1300 compared with 340 for pentamidine). HAPT1 and LAPT1 were 
first described to transport a range of diamidines,20, 24 which, like the bis-phosphonium 
compounds described here, are dications. Our CoMFA models show the importance of 
considerable positive charge dispersion over a large surface for increased activity. On 
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balance, we conclude that, similar to a series of dicationic choline-derived compounds 
on which we recently reported,25 the antitrypanosomal activity is not dependent on entry 
through any of these transporters. In fact, it is highly probable that diffusion is the route 
of entry. This interpretation is much strengthened by the observation that substituents 
such as furan, pyridine and phenylsulphonate, which can engage in H-bonding, display 
significantly reduced antitrypanosomal activities, presumably because of impeded 
cellular penetration. The data presented in Table 4 clearly show that mono-
phosphonium compounds have as good and often slightly better activity against 
trypanosomes than the corresponding symmetrical bis-phosphonium analogs. However, 
this improved activity is in many cases also coupled to somewhat increased toxicity 
against the mammalian cell lines employed. The redundancy of the second 
phosphonium group is consistent with the observation that longer, more flexible linkers 
(i.e., ethylene instead of methylene linker) between the phosphonium cation and the 
central diphenyl core hardly affected the antitrypanosomal activity. This observation is 
important because mono-phosphonium salts are smaller molecules with 
physicochemical properties (i.e., lower molecular weight, lower clogP) more likely to 
provide good pharmacokinetic behaviour in vivo compared with the bis-phosphonium 
counterparts.  
In their 1979 paper,4 Kinnamon and Steck reported that the monophosphonium 
compound 54 (chloride salt) displayed 100% curative activity (53 mg/kg sc) in a murine 
model of T. b. rhodesiense infection. The bromide analogue 55 was found to be less 
active in vivo than its chloride counterpart. However, no in vitro data was reported. The 
results of our in vitro screening are in agreement with these data as 54 displayed 
between submicromolar and nanomolar activities against T. b. brucei and T. b. 
rhodesiense, respectively.  
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The excellent in vitro antitrypanosomal activity observed with this set of phosphonium 
compounds confirms the potential of this class of molecules. We show that 
phosphonium compounds irreversibly inhibit trypanosome growth, leading to certain 
clearance of the population after only a minimum exposure time. This situation is 
similar to that of the highly successful class of diamidine trypanocides, which also 
require only a brief exposure time to ultimately kill the trypanosomes after 1 – 2 days.26 
This result is important for potential therapeutic applications, as dosage can be kept 
relatively low and a single administration may be sufficient, similar to the single 
administration of the diamidine diminazene aceturate that is the routine treatment for 
animal trypanosomiasis.2 In addition, the positive correlation with lipophilicity and thus 
membrane penetration should increase penetration into the central nervous system – 
essential for treatment of late stage trypanosomiasis.3  
 
 Conclusions 
The in vitro screening of a set of 83 phosphonium salt derivatives against African 
trypanosomes allowed the discovery of several trypanocidal compounds with nanomolar 
activities and adequate selectivities vs HEK and L6-cells. SAR studies showed that 
bulky substituents around the phosphonium cations (ie, either C5-C8 homoalkyl chains 
or phenyl rings) are necessary to get submicromolar activities, whereas the linkers have 
less influence on the antitrypanosomal activity. However, this statement is true as far as 
the bisphosphonium salts are concerned. On the contrary, the diphenylether linker 
seemed to be preferred in the case of monophosphonium compounds. In fact, 56c and 
57c were the most active compounds of all the series with EC50 values in the low 
nanomolar range against wild type and resistant T.  brucei lines.  
 30 
Phosphonium compounds displayed a very similar structure-activity relationship against 
T. brucei and Leishmania.5 This observation strongly suggests a similar mechanism of 
action against the two parasite species, and indicates that this class may have broad anti-
protozoal activity. This is the subject of ongoing investigations in our laboratories.  
Importantly, the screening reported here confirmed that there is no cross-resistance 
between the new compounds and existing diamidines and arsenical trypanocides, an 
essential condition for any new preclinical candidate. 
Finally, the CoMFA models developed in this work should help in the design of new 
custom-made phosphonium derivatives with improved activity against African 
trypanosomes. 
 
Experimental section 
Chemistry. All dry solvents were purchased from Aldrich or Fluka in Sure/Seal bottles. 
All reactions requiring anhydrous conditions or an inert atmosphere were performed 
under a positive pressure of N2. All reactions were monitored by Thin Layer 
Chromatography (TLC) using silica gel 60 F254 plates (Merck) or HPLC–MS. 
Chromatography was performed with Isolute SI prepacked columns. 1H and 13C NMR 
spectra were recorded on a Bruker Advance 300 or Varian Inova 400 spectromether. 
Chemical shifts of the 1H NMR spectra were internally referenced to the residual proton 
resonance of the deuterated solvents: CDCl3 (δ 7.26 ppm), D2O (δ 4.6 ppm), CD3OD (δ 
3.49 ppm) and DMSO (δ 2.49 ppm). J values are given in Hz. Melting points were 
determined in open capillary tubes with a SMP3–Stuart Scientific apparatus or Mettler 
Toledo MP70 melting point system, and are uncorrected. All compounds are >95% pure 
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by HPLC or combustion analysis otherwise noted. Elemental analysis was performed on 
a Heraeus CHN–O Rapid analyser. Analytical results were within ± 0.4 % of the 
theoretical values unless otherwise noted. Analytical HPLC–MS was run with an 
Xbridge C18–3.5 µm (2.1×100mm) column on a Waters 2695 separation module 
coupled with a Waters Micromass ZQ spectromether using electrospray ionization 
(ESI+). The following HPLC conditions were used: column temperature = 30 ºC, 
gradient time = 5 min, H2O/CH3CN (10:90 → 90:10) (HCO2H 0.1 %), flow rate = 0.25 
mL/min, UV detection: diode array (λ = 190−400 nm). Semi-preparative HPLC-MS 
was run with a SunFire Prep C18 – 5 µm (19 × 150 mm) column on a Waters separation 
module (Waters 2545/SFO/2767) coupled to a Waters 3100 Mass Detector using ESI+. 
The fractions were collected with a Waters 2767 Sampler Manager.  
1. General procedure for the synthesis of the bisphosphonium salts. A Kimax tube 
was charged with the appropriate bis-halogenated precursor (100 mg, ~0.28 mmol) and 
flushed with argon. Anhydrous DMF (3 mL) was added followed by the phosphine 
(1.12 mmol, 4 equiv). The tube was flushed with argon, stopped, and the reaction 
mixture was stirred at 100 °C for 20 h. A higher temperature (150 ºC) and longer 
reaction time were necessary with the 4,4’-bischloroethyl linkers 16f and 17g. Different 
workup procedures were used depending on whether the product precipitated from the 
reaction mixture or not. Workup I: the reaction was allowed to cool to room temperature 
and the precipitated product was collected by filtration, rinsed successively with toluene 
and Et2O, and dried under vacuum. Workup II: the reaction mixture was transferred to a 
flask. Then, toluene (10–20 mL) was added to precipitate the product. The flask was 
stored in the fridge overnight. The supernatant was removed and the precipitate was 
rinsed with toluene. Et2O (10 mL) was added and the precipitate was triturated with a 
spatula. The solid was collected, rinsed with Et2O and dried under vacuum. 
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4,4
’
-bis((triethylphosphonio)methyl)diphenylmethane dibromide (19b). The 
reaction was carried out in toluene following the general procedure with 
triethylphosphine and 1b. The product was obtained as a white hygroscopic solid (107 
mg, 65%) following workup I procedure and recrystallization in DMF/Toluene. HPLC 
= 91% pure; mp 246–248 °C. 1H NMR (300 MHz, CDCl3) δ 7.42 (d, J = 5.8, 4H, ArH), 
7.07 (d, J = 7.6, 4H, ArH), 4.23 (d, J = 15.2, 4H, PCH2), 3.88 (s, 2H, PhCH2Ph), 2.46 
(dt, J = 20.5, 7.6, 12H, CH2CH3), 1.23 (dt, J = 17.9, 7.7, 18H, CH2CH3).
 13C NMR (75 
MHz, CDCl3) δ 156.9, 131.9, 123.2, 119.9, 25.6, 25.0, 12.3, 11.6, 6.0. LRMS (ES
+) m/z 
= 429.39 [(M-H)]+, 214.93 [M2+, 100%]. Anal. (C27H44Br2P2) Calc: C, 54.93; H, 7.51; 
Br, 26.91. Found: C, 54.75; H, 7.72; Br, 26.20.  
4,4’-bis((trihexylphosphonio)methyl)benzophenone dibromide (25a). The 
reaction was carried out following the general procedure with trihexylphosphine and 1a 
for 48 h at 80 ºC. The product was obtained as a hygroscopic oily solid after workup II. 
Recrystallization from MeOH/Et2O yielded a yellowish hygroscopic solid (27%); HPLC 
= 89% pure. 1H NMR (300 MHz, CDCl3) δ 7.63 (d, J = 6.6, 4H, ArH), 7.50 (d, J = 7.7, 
4H, ArH), 4.67 (d, J = 16.1, 4H; PCH2Ph), 2.29 (m, 12H, PCH2CH2), 1.6–1.1 (m, 48H, 
(CH2)4), 0.84 (m, 18H, CH3). 
13C NMR (75 MHz, CDCl3) δ 194.9, 136.5 (d, J = 3.4), 
134.3 (d, J = 8.7), 130.6 (d, J = 4.8), 129.8 (d, J = 79.7), 31.1, 30.6 (d, J = 14.7), 27.0 
(d, J = 44.4), 22.4, 21.9 (d, J = 4.6), 19.2 (d, J = 46.1), 14.0. LRMS (ES+) m/z 779.86 
[(M-H)+], 390.11 [M2+, 100%]. ESI–HRMS m/z 390.3233 [M2+] (C51H90OP2 requires 
390.3228). 
 4,4’-bis((trihexylphosphonio)methyl)diphenylmethane dibromide (25b). The 
reaction was carried out following the general procedure with trihexylphosphine and 1b. 
The reaction was concentrated to ca. 1 mL to give a yellowish oil that was diluted with 
toluene (10 mL). Addition of Et2O (10 mL) caused precipitation of an oily residue. The 
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flask was stored in the fridge overnight. The supernatant was removed and the oily 
precipitate was rinsed with toluene. Et2O (10 mL) was added to the oily precipitate, 
which was triturated with a spatula to yield 25b as a white solid (158.7 mg, 64%); mp 
111–112 ºC with previous softening (DMF/toluene); HPLC > 94% pure; 1H NMR (300 
MHz, CDCl3) δ 7.38 (dd, J = 8.3, 2.0, 4H, ArH), 7.08 (d, J = 8.3, 4H, ArH), 4.23 (d, J = 
15.1, 4H, PCH2), 3.89 (s, 2H, PhCH2Ph), 2.33 (br s, 12H, CH2), 1.42 (br s, 24H, CH2), 
1.23 (br s, 24H, CH2), 0.85 (t, J = 6.6, 18H, CH3). 
13C NMR (75 MHz, CDCl3) δ 140.8, 
130.5 (d, J = 4.9), 130.0 (d, J = 2.8), 126.5 (d, J = 8.8), 41.1, 31.1, 30.6 (d, J = 14.6), 
26.7 (d, J = 45.2), 22.4, 21.9 (d, J = 4.8), 19.1 (d, J = 46.3), 14.0. LRMS (ES+) m/z 
765.87 [(M-H)+], 383.04 [M2+, 100%]. ESI–HRMS m/z 383.3357 [M2+] (C51H92P2 
requires 383.3332). 
4,4’-bis((phenyldimethylphosphonio)methyl)diphenylethane dibromide 
(28f). The reaction was carried out following the general procedure with 
phenyldimethylphosphine (68.94 mg, 0.497 mmol) and 10f (73.2 mg, 0.199 mmol). The 
reaction was concentrated under vacuum until the formation of an oily solid which was 
diluted with DMF. Et2O was added to precipitate the product as a white hygroscopic 
solid. The flask was allowed to stand in the freezer overnight. The solid was collected, 
rinsed with Et2O and dried under vacuum (106.5 mg, 98%). HPLC > 95% pure; mp 
>300 ºC. 1H NMR (300 MHz, CDCl3) δ 7.80 (dd, J = 12.4, 7.5, 4H, ArH), 7.66 (m, 2H, 
ArH), 7.57 (m, 4H, ArH), 6.98 (dd, J = 3.0, 7.2, 4H, ArH), 6.79 (d, J = 7.5, 4H, ArH), 
4.26 (d, J = 15.4, 4H, PCH2), 2.72 (s, 4H; CH2CH2), 2.30 (d, J = 13.8, 12H, CH3). 
13C 
NMR (75 MHz, CDCl3) δ 141.4 (d, J = 4.1), 134.6 (d, J = 1.8), 131.3 (d, J = 9.7), 130.2 
(d, J = 5.2), 130.0 (d, J = 12.4), 129.4 (d, J = 2.9), 125.4 (d, J = 9.1), 119.8 (d, J = 83.6), 
36.9, 31.2 (d, J = 48.0), 7.5 (d, J = 55.6). LRMS (ES+) m/z = 483.00 [(M-H)]+. ESI–
HRMS m/z 242.1241 [M2+] (C32H38P2 requires 242.1219). 
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4,4’-bis((phenyldimethylphosphonio)methyl)diphenylpropane dibromide 
(28g). The reaction was carried out following the general procedure with 
phenyldimethylphosphine (66 mg, 0.478 mmol) and 11g (73.1 mg, 0.191 mmol). The 
reaction was concentrated under vacuum until the formation of an oily solid which was 
diluted with acetone. Et2O was added to produce precipitation of the product as a dark 
brown hygroscopic solid (67.6 mg, 54 %). HPLC = 90% pure; 1H NMR (300 MHz, 
CDCl3) δ 7.86 – 7.66 (m, 7H, ArH), 7.66 – 7.57 (m, 3H, ArH), 6.98 (t, J = 6.9, 8H, 
ArH), 4.29 (d, J = 15.3, 4H, PCH2), 2.58 – 2.45 (m, 4H, PhCH2CH2), 2.37 (d, J = 13.7, 
12H, CH3), 1.80 (dd, J = 19.2, 11.6, 2H, PhCH2CH2). 
13C NMR (75 MHz, CDCl3) δ 
142.4 (d, J = 4.3), 134.6 (d, J = 3.2), 131.9 (d, J = 9.6), 130.5 (d, J = 5.5), 130.1 (d, J = 
12.2), 129.2 (d, J = 3.4), 125.3 (d, J = 9.4), 120.2 (d, J = 83.0), 35.1, 32.3, 31.3 (d, J = 
48.1), 7.8 (d, J = 55.5). LRMS (ES+) m/z = 497.48 [(M–H)]+, 248.95 [M2+, 100%]. ESI–
HRMS m/z 249.1316 [M2+] (C33H40P2 requires 249.1297). 
 4,4’-bis((diphenyl-p-tolylphosphonio)methyl)diphenylether 
dibromide (38c). The reaction was carried out following the general procedure with 
diphenyl-p-tolylphosphine and 1c. The product was obtained as a white solid (187 mg, 
66%) following workup II procedure; mp 230 ºC (decomp); HPLC > 97% pure; 1H 
NMR (300 MHz, CDCl3) δ 7.79 – 7.54 (m, 28H, ArH), 7.42 (dd, J = 7.9, 2.8, 4H, ArH), 
7.08 (dd, J = 8.6, 2.4, 4H, ArH), 5.32 (d, J = 14.1, 4H, PCH2), 2.45 (s, 6H, CH3). 
13C 
NMR (75 MHz, CDCl3) δ 156.8 (d, J = 4.0), 146.6 (d, J = 3.0), 135.0 (d, J = 2.7), 134.5 
(d, J = 9.9), 133.2 (d, J = 5.4), 131.1 (d, J = 12.9), 130.2 (d, J = 12.5), 122.4 (d, J = 8.6), 
119.1 (d, J = 3.0), 118.1 (d, J = 85.7), 114.0 (d, J = 88.1), 30.1 (d, J = 47.3), 22.0. 
LRMS (ES+) m/z 747.52 [(M-H)+], 373.94 [M2+, 100%]. ESI–HRMS m/z 374.1536 
[M2+] (C52H46OP2 requires 374.1506). 
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 4,4’-bis((tri-4-methoxyphenylphosphonio)methyl)benzophenone 
dibromide (41a). The reaction was carried out following the general procedure with 
tris(4-methoxyphenyl)phosphine and 1a for 22h. The product was obtained as a white 
solid (214.5 mg, 74%) following workup I procedure; mp 244.2–245 ºC; HPLC > 95% 
pure. 1H NMR (300 MHz, CDCl3) δ 7.64 (dd, J = 11.9, 8.8, 14H, ArH), 7.34 (d, J = 7.7, 
4H, ArH), 7.25 – 7.19 (m, 4H, ArH), 7.07 (dd, J = 8.8, 2.4, 14H, ArH), 5.38 (d, J = 
15.2, 4H, PCH2), 3.88 (s, 18H, CH3). 
13C NMR (75 MHz, CDCl3) δ 195.3, 164.7 (d, J = 
2.9), 136.5 (d, J = 11.5), 133.6 (d, J = 8.6), 131.7 (d, J = 5.3), 130.1 (d, J = 2.7), 115.9 
(d, J = 13.8), 109.1, 107.9, 56.0, 31.6 (d, J = 48.7). LRMS (ES+) m/z 911.46 [(M-H)+], 
455.97 [M2+, 100%]. ESI–HRMS m/z 456.1683 [M2+] (C57H54O7P2 requires 456.1667). 
4,4’-bis((tri(2-methoxyphenyl)phosphonio)methyl)diphenylmethane 
dibromide (43b). The reaction was carried out following the general procedure at 50 °C 
instead of 100 °C with tri-2-methoxyphenylphosphine and 1b. The product was 
obtained as a white solid (259.7 mg, 93%) following workup II procedure; mp 210–213 
ºC with previous softening (DMF/toluene); HPLC > 97% pure; 1H NMR (300 MHz, 
CDCl3) δ 7.73 (t, J = 7.9, 6H, ArH), 7.33 – 7.23 (m, 8H, ArH), 7.18 – 7.09 (m, 10H, 
ArH), 6.88 (d, J = 8.0, 4H, ArH), 6.79 (d, J = 8.0, 4H, ArH), 4.58 (d, J = 15.9, 4H, 
PCH2), 3.73 (s, 2H, CH2), 3.63 (s, 18H, CH3). 
13C NMR (75 MHz, CDCl3) δ 161.4 (d, J 
= 2.3), 140.5 (dd, J = 3.4, 1.2), 137.4 (d, J = 1.9), 135.2 (d, J = 8.2), 130.0 (d, J = 7.2), 
129.1 (d, J = 2.3), 128.2 (d, J = 8.0), 122.1 (d, J = 12.8), 112.9 (d, J = 6.7), 105.7 (d, J = 
91.8), 56.5, 40.9, 30.7 (d, J = 52.7). LRMS (ES+) m/z 897.60 [(M-H)+], 448.90 [M2+, 
100%]. ESI–HRMS m/z 449.1816 [M2+] (C57H56O6P2 requires 449.1771). 
 4,4’-bis((tri(2-methoxyphenyl)phosphonio)methyl)diphenylether 
dibromide (43c). The reaction was carried out following the general procedure at 50 °C 
instead of 100 °C with tri-2-methoxyphenylphosphine and 1c. The product was obtained 
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as a white solid (231.3 mg, 85%) following workup II procedure; mp 186–187 ºC with 
previous softening (DMF/toluene); HPLC > 96% pure; 1H NMR (300 MHz, CDCl3) δ 
7.74 (t, J = 7.8, 6H, ArH), 7.37 – 7.27 (m, 6H, ArH), 7.19 – 7.11 (m, 12H, ArH), 6.95 
(dd, J = 17.0, 15.0, 4H, ArH), 6.58 (d, J = 8.3, 4H, ArH), 4.62 (d, J = 15.6, 4H, PCH2), 
3.70 (s, 18H, CH3). 
13C NMR (75 MHz, CDCl3) δ 161.4 (d, J = 2.3), 156.4 (d, J = 3.5), 
137.4 (d, J = 1.6), 135.2 (d, J = 8.2), 131.5 (d, J = 7.2), 125.4 (d, J = 7.8), 122.2 (d, J = 
12.8), 119.0 (d, J = 2.2), 112.9 (d, J = 6.8), 105.8 (d, J = 91.9), 56.5, 30.3 (d, J = 52.6). 
LRMS (ES+) m/z 899.63 [(M-H)+], 449.88 [M2+, 100%]. ESI–HRMS m/z 450.1699 
[M2+] (C56H54O7P2 requires 450.1667). 
4,4’-bis((tri-p-tolylphosphonio)methyl)benzophenone dibromide (45a). The 
reaction was carried out following the general procesude with tri-p-tolylphosphine and 
1a. The product was obtained as a white solid (213.9 mg, 78%) following workup II 
procedure; mp 308.8 ºC (decomp.); HPLC > 95% pure. 1H NMR (300 MHz, CDCl3) δ 
7.61 (dd, J = 12.4, 8.2, 12H, ArH), 7.40 (dd, J = 8.1, 3.1, 12H, ArH), 7.35 (d, J = 8.2, 
4H, ArH), 7.25 - 7.20 (m, 4H, ArH), 5.50 (d, J = 15.2, 4H, PCH2), 2.45 (s, 18H, CH3).
 
13C NMR (75 MHz, CDCl3) δ 195.4, 146.3 (d, J = 3.0), 136.5 (d, J = 3.7), 134.5 (d, J = 
10.3), 133.2 (d, J = 8.6), 131.8 (d, J = 5.4), 131.0 (d, J = 13.1), 130.1 (d, J = 2.8), 114.6 
(d, J = 88.7), 30.9 (d, J = 47.8), 22.0. LRMS (ES+) m/z 815.42 [(M-H)+], 407.81 [M2+, 
100%]. ESI–HRMS m/z 408.1852 [M2+] (C57H54OP2 requires 408.1819). 
4,4’-bis((tri-p-tolylphosphonio)methyl)diphenylether dibromide (45c). The 
reaction was carried out following the general procedure with tri-p-tolylphosphine and 
1c. The product was obtained as a white solid (149.3 mg, 57%) following workup II 
procedure and recrystallization from EtOH/Et2O; mp >300 ºC with previous softening 
(DMF/EtOH); HPLC > 93% pure; 1H NMR (300 MHz, CDCl3) δ 7.54 (dd, J = 12.2, 
8.2, 12H, ArH), 7.45 – 7.36(m, 12H, ArH), 7.08 (dd, J = 8.4, 2.2, 4H, ArH), 6.66 (d, J = 
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8.4, 4H, ArH), 5.18 (d, J = 14.0, 4H, PCH2), 2.44 (s, 18H, CH3). 
13C NMR (75 MHz, 
CDCl3) δ 156.8 (d, J = 3.9), 146.3 (d, J = 3.2), 134.3 (d, J = 10.1), 133.1 (d, J = 5.4), 
131.0 (d, J = 12.9), 122.6 (d, J = 8.5), 119.1 (d, J = 3.0), 114.7 (d, J = 88.4), 30.4 (d, J = 
48.2), 22.0. LRMS (ES+) m/z 803.59 [(M-H)+], 401.93 [M2+, 100%]. ESI–HRMS m/z 
402.1857 [M2+] (C56H54OP2 requires 402.1819). 
 4,4’-bis((tri(p-tolyl)phosphonio)methyl)diphenylacetamide dibromide (45e). 
The reaction was carried out following the general procedure at 100 °C with tri-p-
tolylphosphine and 1e. The product was obtained as a highly hygroscopic white solid 
(72 mg, 53%) following workup II procedure; HPLC > 96% pure; 1H NMR (300 MHz, 
CDCl3) δ 7.63 – 7.47 (m, 14H, ArH), 7.41 (m, 10H, ArH), 7.15 (m, 4H, ArH), 6.94 (d, J 
= 7.4, 4H, ArH), 5.25 (d, J = 15.8, 4H, PCH2), 2.45 (s, 18H, CH3), 1.94 (s, 3H, 
COCH3).
 13C NMR (75 MHz, CDCl3) δ 170.4, 146.5 (d, J = 2.7), 142.7 (d, J = 3.0), 
134.3 (d, J = 10.2), 133.4 – 132.1 (br), 131.1 (d, J = 12.9), 114.5 (d, J = 88.6), 30.8 (d, J 
= 48.2), 24.0, 22.0. LRMS (ES+) m/z 844.61 [(M-H)+], 422.58 [M2+, 100%]. ESI–
HRMS m/z 422.6984 [M2+] (C58H57NOP2 requires 422.6952). 
4,4’-bis((tri-2-thienylphosphonio)methyl)benzophenone dibromide (47a). 
The reaction was carried out following the general procedure with tri-2-
thienylphosphine and 1a (110 mg, 0.3 mmol) for 18 h. The product was obtained as an 
off-white solid after workup II and recrystallization from EtOH (200 mg, 72%); HPLC> 
95% pure. 1H NMR (300 MHz, CDCl3) δ 8.12 (m, 12H, ArH), 7.41 (dt, J = 6.8, 6.2, 
10H, ArH), 7.24 (dd, J = 8.2, 2.6, 4H, ArH), 5.26 (d, J = 15.4, 4H, PCH2). 
13C NMR (75 
MHz, CDCl3) δ 195.3, 143.1 (d, J = 11.8), 140.3 (d, J = 5.4), 137.1 (d, J = 4.3), 132.0 
(d, J = 9.5), 131.5 (d, J = 6.1), 131.0 (d, J = 16.1), 130.4 (d, J = 3.6), 117.1 (d, J = 
109.4), 36.0 (d, J = 53.4). LRMS (ES+) m/z 767.1 [(M-H)+], 383.74 [M2+, 100%]. ESI–
HRMS m/z 384.0085 [M2+] (C39H30OS6P2 requires 384.0043). 
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 4,4’-bis((tri(1-naphthyl)phosphonio)methyl)diphenylmethane 
dibromide (53b). The reaction was carried out following the general procedure with tri-
1-naphthylphosphine and 1b. The product was obtained as a white solid (229.2 mg, 
71%) following workup I procedure and recrystallization from EtOH/Et2O; mp 230 ºC 
(decomp); HPLC > 95% pure; 1H NMR (300 MHz, CDCl3) δ 8.56 (d, J = 11.5, 6H, 
ArH), 8.23 (d, J = 7.5, 6H, ArH), 7.89 (dd, J = 26.8, 8.0, 12H, ArH), 7.68 (br s, 6H, 
ArH), 7.41 (dt, J = 14.7, 7.1, 12H, ArH), 6.72 (d, J = 7.0, 4H, ArH), 6.25 (d, J = 7.0, 
4H, ArH), 5.66 (d, J = 11.3, 4H, PCH2), 3.30 (s, 2H, CH2). 
13C NMR (75 MHz, CDCl3) 
δ 140.5 (d, J = 2.6), 138.5 (d, J = 10.8), 137.1 (d, J = 2.8), 134.3 (d, J = 9.6), 132.6 (d, J 
= 8.4), 130.7 (d, J = 6.7), 130.5, 129.0, 128.8 (d, J = 2.1), 127.6, 126.7 (d, J = 7.5), 
125.9 – 125.6 (m), 114.6 (d, J = 80.9), 40.6, 33.3 (d, J = 48.1). LRMS (ES+) m/z 
1017.77 [(M-H)+], 508.96 [M2+, 100%]. ESI–HRMS m/z 509.1968 [M2+] (C75H56P2 
requires 509.1923). 
4,4’-bis((tri-p-tolylphosphonio)ethyl)diphenylethane dichloride (64). The 
reaction was carried out following the general procedure with tri-p-tolylphosphine and 
16f for 15 days. The reaction was evaporated to dryness forming a yellowish oil which 
was purified by semi-preparative HPLC-MS. IThe following HPLC conditions were 
used: column temperature = 25 ºC, gradient time = 10 min, CH3CN/H2O 
(30:70→100:0) (HCO2H 0.1 %), flow rate = 0.24 mL/min, UV detection: diode array (λ 
= 230 nm). Rt = 6.38 min. The fractions containing the pure product were combined and 
lyophilized to give a white hygroscopic solid (12.6 mg, 5%). HPLC > 99% pure;. 1H 
NMR (300 MHz, CDCl3) δ 7.62 (dd, J = 12.3, 8.1, 12H, ArH), 7.54 – 7.41 (m, 12H, 
ArH), 7.09 (d, J = 7.8, 4H, ArH), 6.95 (d, J = 7.8, 4H, ArH), 3.79 – 3.58 (m, 4H, 
PCH2), 2.99 – 2.84 (m, 4H, PhCH2CH2P), 2.81 (s, 4H, CH2CH2), 2.48 (s, 18H, CH3).
 
13C NMR (75 MHz, CDCl3) δ 146.8, 142.6 (d, J = 2.5), 136.7, 133.5 (dd, J = 10.1, 2.4), 
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132.2 (d, J = 10.4), 129.3 (d, J = 12.6), 128.7, 114.6 (dd, J = 88.1, 2.6), 37.6, 35.0, 28.1 
(d, J = 1.4), 22.0. LRMS (ES+) m/z = 843.39 [(M-H)]+, 422.00 [M2+, 100%]. ESI–
HRMS m/z 422.2181 [M2+] (C60H62P2 requires 422.2158). 
4,4’-bis((tri-p-tolylphosphonio)ethyl)diphenylpropane dichloride (65). The 
reaction was carried out following the general procedure with tri-p-tolylphosphine and 
17g for 19 days. The reaction was evaporated to dryness forming a yellowish oil which 
was purified by semi-preparative HPLC-MS eluting with H2O/CH3CN. The following 
HPLC conditions were used: column temperature = 25 ºC, gradient time = 15 min, 
CH3CN/H2O (30:70→70:30) (HCO2H 0.1 %), flow rate = 0.24 mL/min, UV detection: 
diode array (λ = 240 nm). Rt = 10.32 min. The fractions containing the pure product 
were combined and lyophilized to give a white hygroscopic solid (17.3 mg, 17%). 
HPLC > 99% pure. 1H NMR (300 MHz, CDCl3) δ  7.72–7.55 (m, 12H, ArH), 7.53 – 
7.43 (m, 12H, ArH), 7.14 (d, J = 7.4, 4H, ArH), 7.04 (d, J = 7.4, 4H, ArH), 3.78 (br m, 
4H, PCH2), 2.95 (br m, 4H, CH2), 2.60–2.41 (m, 22H, CH2 and CH3), 1.86 (dt, J = 14.3, 
7.4, 2H, CH2CH2CH2).
 13C NMR (75 MHz, CDCl3) δ 146.4 (dd, J = 5.1, 3.0), 142.3 (d, 
J = 2.8), 135.5 (d, J = 24.9), 133.6 (dd, J = 10.4, 2.6), 132.2 (d, J = 10.3), 129.3 (d, J = 
12.5), 128.6 (d, J = 7.2), 115.1 (dd, J = 88.4, 7.2), 34.6, 33.0, 28.1 (d, J = 3.1), 24.8 (d, J 
= 50.1), 22.0. LRMS (ES+) m/z = 857.88 [(M-H)]+, 429.21 [M2+, 100%]. ESI–HRMS 
m/z 429.2277 [M2+] (C61H64P2 requires 429.2236). 
 
2. General procedure for the synthesis of the monophosphonium salts. The 
appropriate halogenated precursor (100 mg, ~0.36 mmol) was added to a Kimax tube 
and dissolved in anhydrous DMF (3 mL) under argon atmosphere. The phosphine was 
then added (0.72 mmol, 2 equiv.) and the reaction mixture was stirred at 100 °C for 20 
h. Next, the reaction mixture was transferred to a flask and DMF was evaporated under 
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vacuum. Subsequently, toluene (10–20 mL) was added to precipitate the product and 
the flask was stored in the fridge overnight. The supernatant was removed and the 
precipitate was rinsed with toluene. Et2O (10 mL) was added and the precipitate was 
triturated with a spatula. The solid was collected, rinsed with Et2O and dried under 
vacuum. 
(4-benzoylbenzyl)tri-p-tolylphosphonium bromide (56a). The reaction was 
carried out following the general procedure with 2a and tri-p-tolylphosphine. The 
product was obtained as a white solid following workup II procedure (117.6 mg, 56%). 
HPLC > 95% pure; mp 233 °C. 1H NMR (300 MHz, CDCl3) δ 7.68 (dd, J = 3.0, 6.5, 
2H, ArH), 7.62–7.50 (m, 9H, ArH), 7.47–7.32 (m, 8H, ArH), 7.28 (dd, J = 2.3, 8.0, 2H, 
ArH), 5.44 (d, J = 15.0, 2H, PCH2), 2.42 (s, 9H, CH3). 
13C NMR (75 MHz, CDCl3) δ 
196.3, 146.4 (d, J = 3.0), 137.2 (d, J = 3.8), 137.1, 134.3 (d, J = 10.3), 132.8, 132.7, 
131.7 (d, J = 5.4), 130.9 (d, J = 13.0), 130.2 (d, J = 3.1), 130.1, 128.4, 114.4 (d, J = 
88.7), 31.1 (d, J = 48.3), 21.9. LRMS (ES+) m/z = 499.44 [M+]. ESI–HRMS m/z 
499.2203 [M+] (C35H32OP requires 499.2185). 
(4-phenoxybenzyl)tri-p-tolylphosphonium bromide (56c). The reaction was 
carried out following the general procedure with 2c and tri-p-tolylphosphine. The 
product was obtained as a white solid following workup II procedure (94.7 mg, 87%). 
HPLC > 95% pure; mp 192 ºC. 1H NMR (300 MHz, CDCl3) δ 7.56 (dd, J = 7.8, 12.2, 
6H, ArH), 7.47–7.00 (m, 11H, ArH), 6.93 (m, 2H, ArH), 6.76 (d, J = 8.1, 2H, ArH), 
5.20 (d, J = 13.9, 2H, PCH2), 2.45 (s, 9H, CH3). 
13C NMR (75 MHz, CDCl3) δ 157.5 (d, 
J = 3.8), 156.7, 146.3 (d, J = 2.8), 134.4 (d, J = 10.1), 133.1 (d, J = 5.3), 131.0 (d, J = 
12.9), 129.1, 123.8, 122.0 (d, J = 8.5), 119.1, 119.0 (d, J = 2.9), 114.8 (d, J = 88.3), 30.6 
( d, J = 48.4), 22.0. LRMS (ES+) m/z = 487.40 [M+]. ESI–HRMS m/z 487.2206 [M+] 
(C34H32OP requires 487.2185). 
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 (4-phenoxybenzyl)tri-m-tolylphosphonium bromide (57c). The reaction was 
carried out following the general procedure with 2c and tri-m-tolylphosphine. The 
product was obtained as a white solid following workup II procedure (65.2 mg, 60%). 
mp 228.9 ºC. 1H NMR (300 MHz, CDCl3) δ 7.58 – 7.46 (m, 11H, ArH), 7.29 (dd, J = 
14.5, 6.2, 3H, ArH), 7.04 (dd, J = 8.7, 2.4, 3H, ArH), 6.93 (d, J = 7.6, 2H, ArH), 6.75 
(d, J = 8.2, 2H, ArH), 5.29 (d, J = 13.8, 2H, PCH2), 2.41 (s, 9H, CH3).
 13C NMR (75 
MHz, CDCl3) δ 157.7, 156.6, 140.6 (d, J = 12.4), 135.9 (d, J = 2.9), 134.6 (d, J = 9.7), 
133.1 (d, J = 5.4), 131.6 (d, J = 9.7), 130.4 (d, J = 13.2), 128.9, 123.9, 121.9 (d, J = 
8.6), 119.3, 118.8 (d, J = 3.1), 117.9 (d, J = 84.8), 30.4 (d, J = 47.1), 21.6. LRMS (ES+) 
m/z = 487.40 [M]+. Anal. (C32H50BrOP) Calc: C, 71.96; H, 5.68; Br, 14.08. Found: C, 
72.18; H, 5.71; Br, 13.93. 
(4-benzoylbenzyl)tri-n-hexylphosphonium bromide (62a). The reaction was 
carried out following the general procedure with 2a and tri-n-hexylphosphine. The 
product was obtained as a white solid following workup II procedure (84.3 mg, 52%). 
HPLC > 95% pure; mp 109.1 ºC. 1H NMR (300 MHz, CDCl3) δ 7.81 – 7.64 (m, 6H, 
ArH), 7.63 – 7.55 (m, 1H, ArH), 7.47 (t, J = 7.5, 2H, ArH), 4.58 (d, J = 15.9, 2H, 
PhCH2), 2.51 – 2.29 (m, 6H, PCH2CH2), 1.42 (s, 12H, CH2), 1.33 – 1.12 (m, 12H, CH2), 
0.84 (t, J = 6.7, 9H, CH3).
 13C NMR (75 MHz, CDCl3) δ 195.9, 137.6 (d, J = 3.6), 
137.0, 133.7 (d, J = 8.9), 133.0, 131.0 (d, J = 2.9), 130.4 (d, J = 4.9), 129.3 (d, J = 
115.5), 31.1, 30.6 (d, J = 14.8), 22.4, 22.0 (d, J = 4.8), 19.2 (d, J = 46.1), 14.0. LRMS 
(ES+) m/z = 482.36 [(M+H)]+. Anal. (C32H50BrOP) Calc: C, 68.56; H, 8.81; Br, 14.25. 
Found: C, 68.59; H, 8.90; Br, 14.41.  
 
Biology. 
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 In vitro antitrypanosomal activity. The in vitro trypanocidal and cytotoxic 
activities were determined using the Alamar blue assay.27 Detailed experimental 
protocols for these assays with T. b. rhodesiense STIB900 and L6-cells have been 
reported before.28 A slight modification of this protocol was used for the assays with 
wild type and resistant T. b. brucei strains, as described.29 The TbAT1-KO strain is 
derived from the wild type strain T. b. brucei Lister 427 (s427) by deletion of the TbAT1 
gene.18 The B48 strain is a mutant derived from TbAT1-KO by in vitro selection to high 
levels of pentamidine, and does not express a functional High Affinity Pentamidine 
Transporter (HAPT1).8 Monitoring of trypanosome cellular integrity with propidium 
iodide was performed exactly as described previously.25  
 Pentamidine transport assays. Uptake assays used [3H]-pentamidine (Amersham) at 
either 30 nM final concentration for the assessment of HAPT1-mediated transport, or at 
1 µM for the assessment of LAPT1-mediated transport, exactly as described.20, 30 
Briefly, trypanosomes were grown in HMI-9 with 10% Fetal Bovine Serum (FBS) until 
late-log phase, harvested and washed into assay buffer (33 mM HEPES, 98 mM NaCl, 
4.6 mM KCl, 0.55 mM CaCl2, 0.07 mM MgSO4, 5.8 mM NaH2PO4, 0.3 mM MgCl2, 23 
mM NaHCO3, 14 mM glucose, pH 7.3) prior to use in the assay. Cells were incubated 
with radiolabel for 60 s or 120 s for HAPT1 and LAPT1 assays, respectively. 
Incubations were stopped by the addition of 2 mM ice-cold unlabeled pentamidine and 
immediate centrifugation through oil. Quantification was through scintillation counting 
and curves were fitted to sigmoid curves using the Prism 5.0 software package. All 
experiments were performed in triplicate and on at least three fully independent 
occasions. 
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CoMFA Models. The set of compounds (78 in total) were converted to 3D structures 
using LigPrep31 considering pH 7.0 for the protonation state. Nevertheless, only one 
compound within the set, 49a, showed an additional protonation at the fixed pH for the 
pyridine moiety. Both states were modelled and it turned out that the protonated state 
was more consistent with the modelled data. We removed all counter ions, which is why 
compounds 45a, 45f, 45g, 64 and 65 were not included in the modelling step. Atomic 
charges used for the CoMFA models were calculated at the AM132 semiempirical level 
using Gaussian 03.33 
The whole set was divided into two subsets: training compounds and test compounds in 
order to properly validate the models. It was considered as important to have a good 
balance between active and inactive compounds within the test set for the sake of 
keeping a predictive model. With this goal in mind the whole set was divided into 
active, less active and inactive compounds, doing the random selection upon these three 
subsets trying to keep a similar number of compounds among the three subsets. 
However, during the modelling step the activities (EC50) of some compounds were still 
to be determined, so these compounds were included in the test set. 
The molecular alignment was built with the flexible molecular overlay method (50% 
steric, 50% electrostatic) as included in Discovery Studio, Accelerys,34 using the 
selected conformations of the more active compound in the training set as reference. 
Erroneously fitted compounds were re-aligned manually defining pairs of atoms 
ensuring a maximum molecular surface overlay. The resulting conformations on the 
whole set were checked to verify that no unusual energy penalty is paid for the resulting 
conformations.  
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Four different alignments were used within this work based on the four more stable 
conformations, whilst keeping significantly different Root Mean Square Deviations 
(RMSD), found for the more active compound. Here we only present the results on one 
alignment, the one corresponding to the lowest energy conformations, given that it 
yields the better results. In any case no remarkable differences were found for the four 
calculated molecular overlays. CoMFA descriptors calculation (standard CoMFA, HB 
and index), PLS model fitting, region focusing and models validations were conducted 
in the standard manner described within the Sybyl suite35 and we found that standard 
CoMFA descriptors were perfectly able to model the proposed end point. Energetic cut 
offs for CoMFA descriptors were set to 30 kcal mol-1 , which was more suitable for T. 
b. brucei than other calculated values.  
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Supporting Information Available: Synthesis and characterization of the new 
phosphonium salt derivatives 19c, 23b-e, 25c, 28b-c, 33b-c, 34b-c, 35a, 38b, 39a, 40a, 
42a, 43a, 44a-c, 45a, 45b, 45d, 45f, 45g, 46b-c, 50a, 51b-c, 52b-c, 53a, 53c, 57a-61a, 
63a, and the linkers 2a, 3a, 10f, 11g, 12f, 13g, 16f and 17g. QSAR results table and 
molecular overlay. Effect of compounds 25b, 25c, 26a, 35a, 36a, 38a, 43a, 43c, 45d, 
45e, 47a, and 55 on parasite viability as determined with the propidium iodide assay. 
This material is available free of charge via the internet at http://pubs.acs.org. 
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